RxDoctor Payments Data

Leonardo Saulle, MD

Cardiovascular Disease · New Hyde Park, NYNPI 1023052578

Payments from drug & device makers

$14,873in general payments, 2019–2025

Across 446 payments — averaging $33.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Atricure, Inc.$2K
  • Amgen$1K
  • Boston Scientific$968
  • E.r. Squibb & Sons, L.L.C.$931
  • Merck$914
  • plus $7K from 33 others

What the payments were for

  • Food & beverage$14,873100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,873 in reported general payments places this provider in the 80th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$467,571
Medicare patients
381
Services billed
5,054

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban117$152,364
XareltoRivaroxaban83$87,026
EntrestoSacubitril/Valsartan59$57,307
VerquvoVericiguat55$53,406
FarxigaDapagliflozin Propanediol42$35,102
Repatha SureclickEvolocumab21$15,999
JardianceEmpagliflozin18$15,190
NexlizetBempedoic Acid/Ezetimibe13$5,808
Metoprolol Succinate231$3,582
Atorvastatin Calcium168$2,028
Rosuvastatin Calcium110$1,784
Ranolazine ErRanolazine11$1,410
Diltiazem 24hr Er (Cd)Diltiazem Hcl29$1,377
Amlodipine Besylate213$1,329
Chlorthalidone80$1,282

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$530$152,364117 claims
Johnson & JohnsonXarelto$2,226$87,02683 claims
NovartisEntresto$346$57,30759 claims
MerckVerquvo$914$53,40655 claims
AstraZenecaFarxiga$599$35,10242 claims
Boehringer IngelheimJardiance$451$15,19018 claims
Esperion Therapeutics, Inc.Nexlizet$89$5,80813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in New Hyde Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →